The aging of subjects with hepatitis C virus and the impact of dual oral therapy for elder hepatitis C patients

Abstract

Saga University and Saga prefecture health promotion division assemble a hepatic disease database from 2012. Subjects with HCV in this database were analyzed. Two thousand four hundred and sixty subjects with HCV and 3110 subjects received reimbursement for HCV anti-viral treatment were analyzed. Subjects with HCV were born earlier than subjects received reimbursement (1944±12 vs. 1952±12, p<0.001). Subjects received reimbursement had a lower rate of subjects born in -1939 than subjects with HCV (11.5% vs. 38.6%, p<0.001). Subjects with dual oral therapy had a higher rate of patients born in -1939 than conventional interferon-based treatments (p<0.001). It is possible that dual oral therapy achieve more effective anti-viral treatment for elder HCV patients. We can predict that both untreated patients and post-treatment persons will be aging with the rise of treatment. The countermeasures to hepatitis on the aging are important.